Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zandelisib - MEI Pharma/Kyowa Kirin

Drug Profile

Zandelisib - MEI Pharma/Kyowa Kirin

Alternative Names: ACC 524; ME-401; PW 143; PWT 143

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pathway Therapeutics
  • Developer BeiGene; Kyowa Kirin; MEI Pharma
  • Class Amines; Antineoplastics; Benzimidazoles; Inorganic sulfur compounds; Morpholines; Piperidines; Small molecules; Triazines
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Follicular lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma

Most Recent Events

  • 08 Jun 2023 Updated efficacy and adverse events data from the phase II MIRAGE trial in B-cell lymphoma presented at the 28th Congress of the European Haematology Association (EHA-2023)
  • 05 May 2023 MEI Pharma terminates a phase I trial in Chronic lymphocytic leukaemia and Follicular lymphoma (Combination therapy, Second-line therapy or greater) in USA and Switzerland (PO) due to discontinuation of zandelisib program (NCT02914938)
  • 05 May 2023 MEI Pharma terminates a phase I trial in Chronic lymphocytic leukaemia and Follicular lymphoma (Monotherapy, Second-line therapy or greater) in USA and Switzerland (PO) due to discontinuation of zandelisib program (NCT02914938)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top